Amidst concerns over rising oil prices and overcapacity, Delta Air Lines (DAL), the biggest US carrier by market value, reported first quarter 2018 results, with reported net income declining 2.5% to $547 million and diluted EPS remaining flat year-over-year at $0.77 per share. Adjusted EPS jumped 4.2% year-over-year to $0.74.
Reported operating revenue, meanwhile, surged 9.5% to $9.96 billion, driven by a 3% increase in cargo revenue and a $78 million surge in total loyalty revenue. The airline’s bottomline was also impacted by rising costs related to fuel and related taxes. Expenses in ancillary businesses and refinery increased double-digits during the quarter.
Delta’s total unit revenue, excluding refinery sales, jumped 5% with foreign currency contributing about 0.5 points of benefit. Delta is also seeing its best revenue momentum since 2014, with positive domestic unit revenues, improvements in all international entities, strong demand for corporate travel and double-digit increases in loyalty revenues. The company expects to maintain this momentum going forward and deliver total revenue growth of 4% to 6% for the full year.
The stock surged 2.5% in pre-market trading, post the earnings results.
Geographic Highlights
The company saw all its geographic regions deliver positive results, with the Atlantic region reporting double-digit increase in revenue and others posting single-digit increases.
Guidance
For the second quarter of 2018, the company expects EPS in the range of $1.80 to $2.00, while total unit revenue, excluding refinery sales, is expected to be up 3% to 5% year-over-year. On a year-over-year basis, CASM, excluding fuel and profit sharing, is expected to be up 1% to 3% and system capacity is anticipated to increase 3% to 4%.
Earlier in the week United (UAL), American (AAL) and JetBlue (JBLU) raised their Q1 unit revenue targets, in line with Delta, while Southwest Airlines (LUV) cut its unit revenue outlook on the so-called United’s aggressive expansion fears.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on